 | • レポートコード：MRC2-11QY12150 • 出版社/出版日：QYResearch / 2020年11月25日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は血液悪性腫瘍性疾患のグローバル市場について調査・分析したレポートです。種類別（化学療法、免疫療法、標的療法）市場規模、用途別（白血病、リンパ腫、骨髄腫）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別血液悪性腫瘍性疾患の競争状況、市場シェア ・世界の血液悪性腫瘍性疾患市場：種類別市場規模 2015年-2020年（化学療法、免疫療法、標的療法） ・世界の血液悪性腫瘍性疾患市場：種類別市場規模予測 2021年-2026年（化学療法、免疫療法、標的療法） ・世界の血液悪性腫瘍性疾患市場：用途別市場規模 2015年-2020年（白血病、リンパ腫、骨髄腫） ・世界の血液悪性腫瘍性疾患市場：用途別市場規模予測 2021年-2026年（白血病、リンパ腫、骨髄腫） ・北米の血液悪性腫瘍性疾患市場分析：米国、カナダ ・ヨーロッパの血液悪性腫瘍性疾患市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの血液悪性腫瘍性疾患市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の血液悪性腫瘍性疾患市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの血液悪性腫瘍性疾患市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Affymetrix、SkylineDx、AgenaBio、Signal Genetics、Cancer Genetics Inc、Illumina、NeoGenomics、Exiqon、Regulus Therapeutics、Rosetta Genomics、Sequenta、Takeda Pharma、Celgene、Amgen、Ono Pharma、Abbott、BMS、Mundipharma、Novartis、MorphoSys ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Hematological Malignancies Disease Market
The global Hematological Malignancies Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hematological Malignancies Disease Scope and Market Size
Hematological Malignancies Disease market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hematological Malignancies Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Affymetrix
SkylineDx
AgenaBio
Signal Genetics
Cancer Genetics Inc
Illumina
NeoGenomics
Exiqon
Regulus Therapeutics
Rosetta Genomics
Sequenta
Takeda Pharma
Celgene
Amgen
Ono Pharma
Abbott
BMS
Mundipharma
Novartis
MorphoSys
Market segment by Type, the product can be split into
Chemotherapy
Immunotherapy
Targeted Therapy
Market segment by Application, split into
Leukemia
Lymphoma
Myeloma
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hematological Malignancies Disease Revenue
1.4 Market by Type
1.4.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.4.4 Targeted Therapy
1.5 Market by Application
1.5.1 Global Hematological Malignancies Disease Market Share by Application: 2020 VS 2026
1.5.2 Leukemia
1.5.3 Lymphoma
1.5.4 Myeloma
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hematological Malignancies Disease Market Perspective (2015-2026)
2.2 Global Hematological Malignancies Disease Growth Trends by Regions
2.2.1 Hematological Malignancies Disease Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hematological Malignancies Disease Historic Market Share by Regions (2015-2020)
2.2.3 Hematological Malignancies Disease Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hematological Malignancies Disease Market Growth Strategy
2.3.6 Primary Interviews with Key Hematological Malignancies Disease Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancies Disease Players by Market Size
3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2015-2020)
3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2015-2020)
3.1.3 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hematological Malignancies Disease Market Concentration Ratio
3.2.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2019
3.3 Hematological Malignancies Disease Key Players Head office and Area Served
3.4 Key Players Hematological Malignancies Disease Product Solution and Service
3.5 Date of Enter into Hematological Malignancies Disease Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2015-2020)
4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hematological Malignancies Disease Market Size by Application (2015-2020)
5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hematological Malignancies Disease Market Size (2015-2020)
6.2 Hematological Malignancies Disease Key Players in North America (2019-2020)
6.3 North America Hematological Malignancies Disease Market Size by Type (2015-2020)
6.4 North America Hematological Malignancies Disease Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hematological Malignancies Disease Market Size (2015-2020)
7.2 Hematological Malignancies Disease Key Players in Europe (2019-2020)
7.3 Europe Hematological Malignancies Disease Market Size by Type (2015-2020)
7.4 Europe Hematological Malignancies Disease Market Size by Application (2015-2020)
8 China
8.1 China Hematological Malignancies Disease Market Size (2015-2020)
8.2 Hematological Malignancies Disease Key Players in China (2019-2020)
8.3 China Hematological Malignancies Disease Market Size by Type (2015-2020)
8.4 China Hematological Malignancies Disease Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hematological Malignancies Disease Market Size (2015-2020)
9.2 Hematological Malignancies Disease Key Players in Japan (2019-2020)
9.3 Japan Hematological Malignancies Disease Market Size by Type (2015-2020)
9.4 Japan Hematological Malignancies Disease Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hematological Malignancies Disease Market Size (2015-2020)
10.2 Hematological Malignancies Disease Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hematological Malignancies Disease Market Size by Type (2015-2020)
10.4 Southeast Asia Hematological Malignancies Disease Market Size by Application (2015-2020)
11 India
11.1 India Hematological Malignancies Disease Market Size (2015-2020)
11.2 Hematological Malignancies Disease Key Players in India (2019-2020)
11.3 India Hematological Malignancies Disease Market Size by Type (2015-2020)
11.4 India Hematological Malignancies Disease Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hematological Malignancies Disease Market Size (2015-2020)
12.2 Hematological Malignancies Disease Key Players in Central & South America (2019-2020)
12.3 Central & South America Hematological Malignancies Disease Market Size by Type (2015-2020)
12.4 Central & South America Hematological Malignancies Disease Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Affymetrix
13.1.1 Affymetrix Company Details
13.1.2 Affymetrix Business Overview
13.1.3 Affymetrix Hematological Malignancies Disease Introduction
13.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2015-2020))
13.1.5 Affymetrix Recent Development
13.2 SkylineDx
13.2.1 SkylineDx Company Details
13.2.2 SkylineDx Business Overview
13.2.3 SkylineDx Hematological Malignancies Disease Introduction
13.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2015-2020)
13.2.5 SkylineDx Recent Development
13.3 AgenaBio
13.3.1 AgenaBio Company Details
13.3.2 AgenaBio Business Overview
13.3.3 AgenaBio Hematological Malignancies Disease Introduction
13.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2015-2020)
13.3.5 AgenaBio Recent Development
13.4 Signal Genetics
13.4.1 Signal Genetics Company Details
13.4.2 Signal Genetics Business Overview
13.4.3 Signal Genetics Hematological Malignancies Disease Introduction
13.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2015-2020)
13.4.5 Signal Genetics Recent Development
13.5 Cancer Genetics Inc
13.5.1 Cancer Genetics Inc Company Details
13.5.2 Cancer Genetics Inc Business Overview
13.5.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction
13.5.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2015-2020)
13.5.5 Cancer Genetics Inc Recent Development
13.6 Illumina
13.6.1 Illumina Company Details
13.6.2 Illumina Business Overview
13.6.3 Illumina Hematological Malignancies Disease Introduction
13.6.4 Illumina Revenue in Hematological Malignancies Disease Business (2015-2020)
13.6.5 Illumina Recent Development
13.7 NeoGenomics
13.7.1 NeoGenomics Company Details
13.7.2 NeoGenomics Business Overview
13.7.3 NeoGenomics Hematological Malignancies Disease Introduction
13.7.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2015-2020)
13.7.5 NeoGenomics Recent Development
13.8 Exiqon
13.8.1 Exiqon Company Details
13.8.2 Exiqon Business Overview
13.8.3 Exiqon Hematological Malignancies Disease Introduction
13.8.4 Exiqon Revenue in Hematological Malignancies Disease Business (2015-2020)
13.8.5 Exiqon Recent Development
13.9 Regulus Therapeutics
13.9.1 Regulus Therapeutics Company Details
13.9.2 Regulus Therapeutics Business Overview
13.9.3 Regulus Therapeutics Hematological Malignancies Disease Introduction
13.9.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2015-2020)
13.9.5 Regulus Therapeutics Recent Development
13.10 Rosetta Genomics
13.10.1 Rosetta Genomics Company Details
13.10.2 Rosetta Genomics Business Overview
13.10.3 Rosetta Genomics Hematological Malignancies Disease Introduction
13.10.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2015-2020)
13.10.5 Rosetta Genomics Recent Development
13.11 Sequenta
10.11.1 Sequenta Company Details
10.11.2 Sequenta Business Overview
10.11.3 Sequenta Hematological Malignancies Disease Introduction
10.11.4 Sequenta Revenue in Hematological Malignancies Disease Business (2015-2020)
10.11.5 Sequenta Recent Development
13.12 Takeda Pharma
10.12.1 Takeda Pharma Company Details
10.12.2 Takeda Pharma Business Overview
10.12.3 Takeda Pharma Hematological Malignancies Disease Introduction
10.12.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2015-2020)
10.12.5 Takeda Pharma Recent Development
13.13 Celgene
10.13.1 Celgene Company Details
10.13.2 Celgene Business Overview
10.13.3 Celgene Hematological Malignancies Disease Introduction
10.13.4 Celgene Revenue in Hematological Malignancies Disease Business (2015-2020)
10.13.5 Celgene Recent Development
13.14 Amgen
10.14.1 Amgen Company Details
10.14.2 Amgen Business Overview
10.14.3 Amgen Hematological Malignancies Disease Introduction
10.14.4 Amgen Revenue in Hematological Malignancies Disease Business (2015-2020)
10.14.5 Amgen Recent Development
13.15 Ono Pharma
10.15.1 Ono Pharma Company Details
10.15.2 Ono Pharma Business Overview
10.15.3 Ono Pharma Hematological Malignancies Disease Introduction
10.15.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2015-2020)
10.15.5 Ono Pharma Recent Development
13.16 Abbott
10.16.1 Abbott Company Details
10.16.2 Abbott Business Overview
10.16.3 Abbott Hematological Malignancies Disease Introduction
10.16.4 Abbott Revenue in Hematological Malignancies Disease Business (2015-2020)
10.16.5 Abbott Recent Development
13.17 BMS
10.17.1 BMS Company Details
10.17.2 BMS Business Overview
10.17.3 BMS Hematological Malignancies Disease Introduction
10.17.4 BMS Revenue in Hematological Malignancies Disease Business (2015-2020)
10.17.5 BMS Recent Development
13.18 Mundipharma
10.18.1 Mundipharma Company Details
10.18.2 Mundipharma Business Overview
10.18.3 Mundipharma Hematological Malignancies Disease Introduction
10.18.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2015-2020)
10.18.5 Mundipharma Recent Development
13.19 Novartis
10.19.1 Novartis Company Details
10.19.2 Novartis Business Overview
10.19.3 Novartis Hematological Malignancies Disease Introduction
10.19.4 Novartis Revenue in Hematological Malignancies Disease Business (2015-2020)
10.19.5 Novartis Recent Development
13.20 MorphoSys
10.20.1 MorphoSys Company Details
10.20.2 MorphoSys Business Overview
10.20.3 MorphoSys Hematological Malignancies Disease Introduction
10.20.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2015-2020)
10.20.5 MorphoSys Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hematological Malignancies Disease Key Market Segments
Table 2. Key Players Covered: Ranking by Hematological Malignancies Disease Revenue
Table 3. Ranking of Global Top Hematological Malignancies Disease Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hematological Malignancies Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Immunotherapy
Table 7. Key Players of Targeted Therapy
Table 8. Global Hematological Malignancies Disease Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Hematological Malignancies Disease Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Hematological Malignancies Disease Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Hematological Malignancies Disease Market Share by Regions (2015-2020)
Table 12. Global Hematological Malignancies Disease Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Hematological Malignancies Disease Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Hematological Malignancies Disease Market Growth Strategy
Table 18. Main Points Interviewed from Key Hematological Malignancies Disease Players
Table 19. Global Hematological Malignancies Disease Revenue by Players (2015-2020) (Million US$)
Table 20. Global Hematological Malignancies Disease Market Share by Players (2015-2020)
Table 21. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2019)
Table 22. Global Hematological Malignancies Disease by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hematological Malignancies Disease Product Solution and Service
Table 25. Date of Enter into Hematological Malignancies Disease Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 28. Global Hematological Malignancies Disease Market Size Share by Type (2015-2020)
Table 29. Global Hematological Malignancies Disease Revenue Market Share by Type (2021-2026)
Table 30. Global Hematological Malignancies Disease Market Size Share by Application (2015-2020)
Table 31. Global Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 32. Global Hematological Malignancies Disease Market Size Share by Application (2021-2026)
Table 33. North America Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 35. North America Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 36. North America Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 37. North America Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 38. North America Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 39. Europe Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 41. Europe Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 43. Europe Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 45. China Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 46. China Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 47. China Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 48. China Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 49. China Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 50. China Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 51. Japan Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 53. Japan Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 55. Japan Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 59. Southeast Asia Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 61. Southeast Asia Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 63. India Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 64. India Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 65. India Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 66. India Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 67. India Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 68. India Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Hematological Malignancies Disease Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Hematological Malignancies Disease Market Share (2019-2020)
Table 71. Central & South America Hematological Malignancies Disease Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Hematological Malignancies Disease Market Share by Type (2015-2020)
Table 73. Central & South America Hematological Malignancies Disease Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Hematological Malignancies Disease Market Share by Application (2015-2020)
Table 75. Affymetrix Company Details
Table 76. Affymetrix Business Overview
Table 77. Affymetrix Product
Table 78. Affymetrix Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 79. Affymetrix Recent Development
Table 80. SkylineDx Company Details
Table 81. SkylineDx Business Overview
Table 82. SkylineDx Product
Table 83. SkylineDx Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 84. SkylineDx Recent Development
Table 85. AgenaBio Company Details
Table 86. AgenaBio Business Overview
Table 87. AgenaBio Product
Table 88. AgenaBio Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 89. AgenaBio Recent Development
Table 90. Signal Genetics Company Details
Table 91. Signal Genetics Business Overview
Table 92. Signal Genetics Product
Table 93. Signal Genetics Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 94. Signal Genetics Recent Development
Table 95. Cancer Genetics Inc Company Details
Table 96. Cancer Genetics Inc Business Overview
Table 97. Cancer Genetics Inc Product
Table 98. Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 99. Cancer Genetics Inc Recent Development
Table 100. Illumina Company Details
Table 101. Illumina Business Overview
Table 102. Illumina Product
Table 103. Illumina Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 104. Illumina Recent Development
Table 105. NeoGenomics Company Details
Table 106. NeoGenomics Business Overview
Table 107. NeoGenomics Product
Table 108. NeoGenomics Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 109. NeoGenomics Recent Development
Table 110. Exiqon Business Overview
Table 111. Exiqon Product
Table 112. Exiqon Company Details
Table 113. Exiqon Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 114. Exiqon Recent Development
Table 115. Regulus Therapeutics Company Details
Table 116. Regulus Therapeutics Business Overview
Table 117. Regulus Therapeutics Product
Table 118. Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 119. Regulus Therapeutics Recent Development
Table 120. Rosetta Genomics Company Details
Table 121. Rosetta Genomics Business Overview
Table 122. Rosetta Genomics Product
Table 123. Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 124. Rosetta Genomics Recent Development
Table 125. Sequenta Company Details
Table 126. Sequenta Business Overview
Table 127. Sequenta Product
Table 128. Sequenta Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 129. Sequenta Recent Development
Table 130. Takeda Pharma Company Details
Table 131. Takeda Pharma Business Overview
Table 132. Takeda Pharma Product
Table 133. Takeda Pharma Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 134. Takeda Pharma Recent Development
Table 135. Celgene Company Details
Table 136. Celgene Business Overview
Table 137. Celgene Product
Table 138. Celgene Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 139. Celgene Recent Development
Table 140. Amgen Company Details
Table 141. Amgen Business Overview
Table 142. Amgen Product
Table 143. Amgen Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 144. Amgen Recent Development
Table 145. Ono Pharma Company Details
Table 146. Ono Pharma Business Overview
Table 147. Ono Pharma Product
Table 148. Ono Pharma Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 149. Ono Pharma Recent Development
Table 150. Abbott Company Details
Table 151. Abbott Business Overview
Table 152. Abbott Product
Table 153. Abbott Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 154. Abbott Recent Development
Table 155. BMS Company Details
Table 156. BMS Business Overview
Table 157. BMS Product
Table 158. BMS Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 159. BMS Recent Development
Table 160. Mundipharma Company Details
Table 161. Mundipharma Business Overview
Table 162. Mundipharma Product
Table 163. Mundipharma Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 164. Mundipharma Recent Development
Table 165. Novartis Company Details
Table 166. Novartis Business Overview
Table 167. Novartis Product
Table 168. Novartis Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 169. Novartis Recent Development
Table 170. MorphoSys Company Details
Table 171. MorphoSys Business Overview
Table 172. MorphoSys Product
Table 173. MorphoSys Revenue in Hematological Malignancies Disease Business (2015-2020) (Million US$)
Table 174. MorphoSys Recent Development
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Malignancies Disease Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Immunotherapy Features
Figure 4. Targeted Therapy Features
Figure 5. Global Hematological Malignancies Disease Market Share by Application: 2020 VS 2026
Figure 6. Leukemia Case Studies
Figure 7. Lymphoma Case Studies
Figure 8. Myeloma Case Studies
Figure 9. Hematological Malignancies Disease Report Years Considered
Figure 10. Global Hematological Malignancies Disease Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Hematological Malignancies Disease Market Share by Regions: 2020 VS 2026
Figure 12. Global Hematological Malignancies Disease Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Hematological Malignancies Disease Market Share by Players in 2019
Figure 15. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2019
Figure 17. North America Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Hematological Malignancies Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
血液悪性腫瘍の世界市場（～2026年） Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Market Analysis and Insights: Global Hematological Malignancies Market The global Hematological Malignancies market size is projected to reach …- 非血液がんの世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 非血液がん治療の世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 血液疾患診断・治療の世界市場（～2026年） Hematology, a branch of medicine, deals with the prevention, diagnosis, and treatment of blood diseases. It includes problems associated with red blood cells (RBCs), white blood cells (WBCs), platelets, bone marrow, blood vessels, spleen, lymph nodes, and proteins involved in bleeding and clotting p…
- キャッスルマン病治療の世界市場（～2026年） Castleman disease is a rare condition of lymph nodes and similar tissues. This condition occurs when too many non-cancer cells started to grow in the lymph node. After initial growth hard growth started to form. Usually, it occurs in the chest, abdomen or neck. This condition is also called as angio…